Lixte Biotechnology (NASDAQ:LIXT) Trading 4.2% Higher – Still a Buy?

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) shot up 4.2% during mid-day trading on Tuesday . The stock traded as high as $7.99 and last traded at $7.51. Approximately 614,310 shares were traded during trading, an increase of 21% from the average session volume of 506,337 shares. The stock had previously closed at $7.21.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on LIXT. Weiss Ratings cut shares of Lixte Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 26th. Wall Street Zen upgraded shares of Lixte Biotechnology to a “hold” rating in a research report on Saturday, June 13th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Lixte Biotechnology Stock Performance

The company has a market cap of $112.80 million, a price-to-earnings ratio of -6.65 and a beta of 1.24. The firm’s 50-day moving average price is $6.25 and its 200 day moving average price is $4.32.

Lixte Biotechnology (NASDAQ:LIXT) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.18) earnings per share for the quarter.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in LIXT. FNY Investment Advisers LLC bought a new position in shares of Lixte Biotechnology during the second quarter worth $330,000. Axxcess Wealth Management LLC acquired a new stake in Lixte Biotechnology during the 4th quarter worth $54,000. XTX Topco Ltd bought a new position in Lixte Biotechnology during the fourth quarter worth about $57,000. Federation des caisses Desjardins du Quebec lifted its holdings in Lixte Biotechnology by 83.6% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock worth $367,000 after acquiring an additional 42,530 shares in the last quarter. Finally, DRW Securities LLC lifted its holdings in Lixte Biotechnology by 11.6% during the fourth quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock worth $213,000 after acquiring an additional 5,645 shares in the last quarter. Institutional investors and hedge funds own 5.10% of the company’s stock.

Lixte Biotechnology Company Profile

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.